Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Merck & Co., Inc. < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence June 21, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health June 21, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults June 21, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection June 13, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference June 08, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study June 07, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline June 07, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial June 05, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Third-Quarter 2022 Dividend May 24, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence May 24, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection May 20, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab) May 10, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Participate in Bank of America Securities 2022 Healthcare Conference May 04, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer April 29, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1) April 29, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces First-Quarter 2022 Financial Results April 28, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) April 25, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces That Joseph Romanelli Will Lead Merck Human Health International, Effective August 1, 2022 April 20, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults April 14, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Hold First-Quarter 2022 Sales and Earnings Conference Call April 28 April 08, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need April 05, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck’s HPV Vaccine Supply and Support Broader and Equitable Access April 04, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children April 01, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo April 01, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors in Five Different Types of Cancer March 25, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1) March 25, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer March 23, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS™ in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT March 22, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation March 21, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression March 17, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.